DOI: 10.35845/kmuj.2020.19677                                                                 CASE REPORT

PRIMARY MYXOPAPILLARY EPENDYMOMA OF FOURTH VENTRICLE: FIRST CASE REPORT IN A TWO-YEAR-OLD CHILD

Uzma Bukhari1, Durr-e-Sameen Kamran1, Hira Salam1

 


1: Dow International Medical and Dental College, Ojha Campus, Karachi, Pakistan.

*Corresponding Author:
Email: hirasalam@gmail.com

Date Submitted: September 03, 2019
Date Last Revised: February 25, 2020
Date Accepted: February 27, 2020


 


THIS ARTICLE MAY BE CITED AS:
Bukhari U, Kamran D-S, Salam H. Primary myxopapillary ependymoma of fourth ventricle: first case report in a two-year-old child. Khyber Med Univ J 2020;12(1):58-60. DOI: 10.35845/kmuj.2020.19677.



ABSTRACT 

Myxopapillary ependymoma (MPE), a rare pathological subtype of ependymoma which shows predilection for middle-aged adults between third and fifth decades of life. It is a benign tumor that primarily occurs at filum terminale of spinal cord with a rare possibility to metastasize to the brain. Primary intracranial MPEs have been reported only rarely. Two-year-old child presented with a space-occupying lesion in fourth ventricle. Based on clinical and radiological findings, particularly owing to patient’s age differential diagnosis of medulloblastoma was considered. Biopsy followed by histopathological and immunohistochemical analysis yielded diagnosis of primary intracranial myxopapillary ependymoma.

In conclusion, MPEs can occur anywhere in intracranial space and in any age group. Despite their indolent behavior, their metastatic potential necessitates thorough investigation to rule out former before establishing diagnosis of primary intracranial MPE.

KEY WORDS: Ependymoma (MeSH); Ependymoma, Myxopapillary (MeSH); Brain Tumor (MeSH); Fourth Ventricle (MeSH); Ependymoglial Cells (MeSH); Brain Neoplasms (MeSH); Pediatric brain tumor (Non-MeSH); WHO grade I (Non-MeSH); Neoplasm Grading (MeSH); Immunohistochemistry (MeSH); Children, Preschool (MeSH).

 

INTRODUCTION

Myxopapillary ependymoma (MPE), a rare pathological subtype of ependymoma which shows predilection for middle aged adults between third and fifth decades of life.1 Despite being categorized under World Health Organization (WHO) Grade-I tumors, MPE harbors tendency for both local relapse and distant spread.1 The tumor has strong predilection for involvement of filum terminale of spinal cord, but MPE can manifest rarely in uncommon sites including brain and subcutaneous tissue.2-4 According to one series, MPE constituted merely 0.3% of all CNS tumors in the pediatric age group.4 According to literature review, only 17 cases of primary intracranial MPEs have been reported.3,5 We present first case of primary intracranial MPE in 2-year-old child, youngest age recorded to date.

 

CASE REPORT 

Two-year-old child presented with a space-occupying lesion in fourth ventricle. On radiological examination, MRI revealed an intraventricular mass lesion in fourth ventricle resulting in obstructive hydrocephalus. No calcifications or hemorrhage were seen. Based on clinical findings, differential diagnosis of medulloblastoma was considered (Figure 1). Biopsy was performed, and specimen sent for histopathological examination for establishment of diagnosis.

Grossly, the biopsy material comprised of multiple pale white soft tissue pieces measuring 4×3×2 cm, collectively. Microscopically, sections examined revealed neoplastic lesion exhibiting characteristic papillary architecture and cuboidal to elongated neoplastic cells with fibrillary background. Individual neoplastic cells show hyperchromatic, vesicular nuclei, small nucleoli and pale cytoplasm. Perivascular pseudo-rosette formation was also noted. Occasional mitotic figures were seen with mitotic count of 1-2 per 10 high power fields. No evidence of increased cellularity, increased mitoses or necrosis was noted. Abundant perivascular mucin with microcyst formation was noted, highlighted on special stain alcian blue (Figure 2). Focally reactive glial tissue is noted.

Immunohistochemical staining was performed and tumor cells were reactive against glial fibrillary acidic protein (GFAP), vimentin and S100. No reactivity was noted against pan-cytokeratin (Figure 3).

Based on radiological and histopathological features, diagnosis of primary intracranial myxopapillary ependymoma was established. Spinal cord MRI excluded possibility of metastasis.

 

 

 

 

DISCUSSION

Ependymomas are relatively uncommon neoplasms of ependymal cell origin constituting 6% of all gliomas, 60% of spinal gliomas, and up to 90% of primary tumors of cauda equina and filum terminale.6,7 MPE was first described as a distinct morphological variant of former by Kernohan in 1932 based on histological findings of papillary architecture, perivascular pseudorosettes and abundance of mucin.4,6

MPEs are slow-growing, WHO grade I tumors manifesting almost exclusively as intraspinal lesions in 3rd or 4th decade of life.7 Slight male predilection with male-to-female ratio of 1.7:1 has been reported. In children, the neoplasm tends to behave more aggressively with greater propensity for CNS metastasis.8 Metastases may develop, albeit rarely, through dissemination via cerebrospinal fluid (CSF) circulation.7,9 Before diagnosis of primary intracranial MPE can be established, radiological imaging of both brain and spinal cord are mandatory.10

Only 17 cases of primary intracranial MPEs have been reported prior to this case. Only three cases have been reported in fourth ventricle, all of which have been females with youngest age at diagnosis recorded at 7 years, which is also the youngest age in which primary intracranial MPEs have been reported up until now. Our case is first to report involvement of fourth ventricle in male patient and youngest age, i.e. 2 years.9

In conclusion, MPEs can occur anywhere in intracranial space and in any age group. Despite their indolent behavior, their metastatic potential necessitates thorough investigation to rule out former before establishing diagnosis of primary intracranial MPE.

 

REFERENCES

  1. Wang H, Zhang S, Rehman SK, Zhang Z, Li W, Makki MS, et al. Clinicopathological features of myxopapillary ependymoma. J Clin Neurosci 2014;21(4):569-73. DOI: 10.1016/j.jocn.2013.05.028.
  2. Salomao JF, de Andrade CV, Bellas AR, Cervante TP. The nature of double concomitant myxopapillary ependymoma: report of a case. Child's Nerv Sys 2014;30(3):527-30. DOI: 10.1007/s00381-013-2251-0.
  3. Khalatbari MR, Moharamzad Y. Primary cerebral myxopapillary ependymoma presenting with intratumoral hemorrhage. Br J Neurosurg 2014;28(4):523-4. DOI: 10.3109/02688697.2013.859656.
  4. Cimino PJ, Agarwal A, Dehner LP. Myxopapillary ependymoma in children: a study of 11 cases and a comparison with the adult experience. Pediatr Blood Cancer 2014;61(11):1969-71. DOI: 10.1002/pbc.25125.
  5. Patangia P, Rai NN, Saxena R, Mandawat PS. Primary intracerebral myxopapillary ependymoma: A rare case report. Annals Pathol Lab Med 2016;3(5):C236-40.
  6. Rogers S, Jones DT, Ireland A, Gottardo NG, Endersby R. Unusual paediatric spinal myxopapillary ependymomas: Unique molecular entities or pathological variations on a theme? J Clin Neurosci 2018;50:144-8. DOI: 10.1016/j.jocn.2018.01.048.
  7. DiLuna ML, Levy GH, Sood S, Duncan CC. Primary myxopapillary ependymoma of the medulla: case report. Neurosurgery 2010;66(6):E1208-9; discussion E9. DOI: 10.1227/01.NEU.0000369513.84063.A6.
  8. Lucchesi KM, Grant R, Kahle KT, Marks AM, DiLuna ML. Primary spinal myxopapillary ependymoma in the pediatric population: a study from the Surveillance, Epidemiology, and End Results (SEER) database. J Neurooncol 2016;130(1):133-40. DOI: 10.1007/s11060-016-2218-6.
  9. Mewada TB, Bishnoi IH, Singh H, Singh D. Occipital Intraparenchymal Myxopapillary Ependymoma: Case Report and Literature Review. Asian J Neurosurg 2017;12(4):731-4. DOI: 10.4103/ajns.AJNS_45_15.
  10. Margetis K, Koutsarnakis C, Stranjalis G. Primary cerebellar myxopapillary ependymoma. J Neurooncol 2011;104(3):839-40. DOI: 10.1007/s11060-011-0535-3. 

  


AUTHORS' CONTRIBUTIONS

Following authors have made substantial contributions to the manuscript as under:

UB & DeSK: Identification, diagnosis & management of the case, critical review, final approval of the version to be published.
HS:  Diagnosis, Manuscript writing and Final approval of the version to be published.

Authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


   


CONFLICT OF INTEREST
Authors declared no conflict of interest

GRANT SUPPORT AND FINANCIAL DISCLOSURE
NIL


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 2.0 Generic License.